Literature DB >> 9791146

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor.

A Carr1, D A Cooper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9791146     DOI： 10.1056/NEJM199810293391806

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  When should antiretroviral therapy for HIV be started?

Authors:  Andrew N Phillips; Brian G Gazzard; Nathan Clumeck; Marcelo H Losso; Jens D Lundgren
Journal:  BMJ       Date:  2007-01-13

Review 3.  Considering metabolic issues when initiating HIV therapy.

Authors:  David Alain Wohl
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

4.  Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.

Authors:  Otilia Elisabeta Benea; Adrian Streinu-Cercel; Carmen Dorobăţ; Sorin Rugină; Lucian Negruţiu; Augustin Cupşa; Dan Duiculescu; Carmen Chiriac; Corina Itu; Liviu Jany Prisăcariu; Ionel Iosif
Journal:  Germs       Date:  2014-09-01

Review 5.  Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?

Authors:  G M Behrens; M Stoll; R E Schmidt
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

6.  Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.

Authors:  Carla M T Fourie; Johannes M Van Rooyen; Annamarie Kruger; Michael H Olsen; Jesper Eugen-Olsen; Rudolph Schutte; Aletta E Schutte
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

7.  Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).

Authors:  Sang Hoon Han; Jialun Zhou; Suneeta Saghayam; Sasheela Vanar; Nittaya Phanuphak; Yi-Ming A Chen; Thira Sirisanthana; Somnuek Sungkanuparph; Christopher K C Lee; Sanjay Pujari; Patrick C K Li; Shinichi Oka; Vonthanak Saphonn; Fujie Zhang; Tuti Parwati Merati; Matthew G Law; Jun Yong Choi
Journal:  Endocr J       Date:  2011-04-27       Impact factor: 2.349

Review 8.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population.

Authors:  Carla Maria T Fourie; Johannes M Van Rooyen; Annamarie Kruger; Aletta E Schutte
Journal:  Lipids       Date:  2009-11-15       Impact factor: 1.880

10.  Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients.

Authors:  B M Bergersen; L Sandvik; O Dunlop; K Birkeland; J N Bruun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-11       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.